Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

NCT01900782 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: Intervention A
BIOLOGICAL: Intervention B
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals